MarketCap
Facebook
X
Telegram
BeiGene, Ltd. Net Income | BGNE
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 287 M | -645 M | -882 M | -2 B | -1.46 B | -1.62 B | -949 M | -674 M | -93.1 M | -119 M | -57.1 M | -18.3 M | -7.49 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 287 M | -2 B | -634 M |
Quarterly Net Income BeiGene, Ltd.
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 237 M | 227 M | 125 M | 94.3 M | 1.27 M | - | -121 M | -120 M | -251 M | - | 215 M | -381 M | -348 M | - | -558 M | -566 M | -435 M | - | -438 M | -485 M | 55.6 M | -473 M | -425 M | -335 M | -364 M | -388 M | -307 M | -85.6 M | -168 M | -268 M | -144 M | -157 M | -105 M | -99.3 M | 117 M | -60.5 M | -50.6 M | -37.6 M | -35.5 M | -24.1 M | -22 M | -27.2 M | -14 M | -5.64 M | -10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 237 M | -566 M | -152 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-84.7 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-60.5 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-1.79 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
-66 M | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-79.5 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-71.2 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-8.38 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-28.9 M | - | - | $ 24.9 M | USA |
 |
Завод ДИОД
DIOD
|
37.2 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-525 M | - | - | - | Russia |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-106 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-28.5 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-132 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-34.4 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-215 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-130 M | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
-4.95 M | $ 1.05 | -7.08 % | $ 6.61 M | USA |
 |
Cellectis S.A.
CLLS
|
-67.6 M | $ 0.98 | 0.51 % | $ 98.3 M |  France |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 11.82 | 3.96 % | $ 3.53 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 58.02 | -0.58 % | $ 7.76 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 55.95 | -1.2 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
-259 M | $ 29.25 | 0.97 % | $ 1.94 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-11.5 M | $ 3.67 | 1.38 % | $ 44.8 M |  Israel |
 |
Jaguar Health
JAGX
|
-54 K | $ 2.04 | -5.12 % | $ 4.76 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-6.6 M | $ 2.55 | -0.58 % | $ 200 M | Israel |
 |
uniQure N.V.
QURE
|
-199 M | $ 22.43 | -2.94 % | $ 1.29 B | Niderland |
 |
Stoke Therapeutics
STOK
|
-6.88 M | $ 25.04 | -2.57 % | $ 1.48 B | USA |
 |
Xencor
XNCR
|
-91.9 M | $ 25.18 | -2.55 % | $ 1.87 B | USA |
 |
Annexon
ANNX
|
-207 M | $ 3.75 | -1.57 % | $ 582 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 1.78 | -2.73 % | $ 2.93 M | Israel |
 |
Incyte Corporation
INCY
|
1.29 B | $ 115.71 | -1.04 % | $ 22.6 B | USA |
 |
Mesoblast Limited
MESO
|
-102 M | $ 12.28 | -2.15 % | $ 14.8 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
-114 M | $ 9.21 | -5.73 % | $ 741 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
3.95 B | $ 523.93 | -2.1 % | $ 134 B | USA |
 |
Abeona Therapeutics
ABEO
|
-71.2 M | $ 4.4 | -1.57 % | $ 233 M | USA |
 |
AbbVie
ABBV
|
1.82 B | $ 285.64 | 0.24 % | $ 505 B | USA |
 |
AIM ImmunoTech
AIM
|
-14 M | $ 0.16 | -4.11 % | $ 259 K | USA |
 |
Akebia Therapeutics
AKBA
|
-5.3 M | $ 0.57 | 0.84 % | $ 147 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 4.2 | -0.24 % | $ 805 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
391 M | $ 19.73 | -2.86 % | $ 3.32 B | USA |
 |
ADC Therapeutics SA
ADCT
|
-143 M | $ 1.44 | -9.72 % | $ 183 M |  Schweiz |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 25.51 | 4.51 % | $ 3.87 B | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
-232 M | $ 0.4 | -5.51 % | $ 29.3 K | USA |
 |
Seagen
SGEN
|
-610 M | - | - | $ 42.2 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-413 M | $ 37.0 | -0.51 % | $ 2.14 B | USA |